Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
NCT05116579 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2024-09-05
Summary
To evaluate the application value of customized ctDNA monitoring in efficacy assessment and prediction during PARPi treatment
Conditions
Sponsors & Collaborators
-
Sun Yat-sen University
lead OTHER
Principal Investigators
-
Yonghong Li, M.D. · Sun Yat-sen University
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-10-31
- Primary Completion
- 2023-03-31
- Completion
- 2025-08-31
Countries
- China
Study Locations
More Related Trials
-
ctDNA-MRD Monitoring After Resection in Gastric Cancer
NCT06893133 ·Status: RECRUITING
-
Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA Sequencing
NCT06036563 ·Status: RECRUITING
-
AssesSment of Early-deteCtion basEd oN liquiD Biopsy in Hepatobiliary Cancer Malignancies
NCT04835675 ·Status: COMPLETED
-
ctDNA Screening in Advanced HER2 Positive Gastric Cancer
NCT04520295 ·Status: UNKNOWN
-
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
NCT06653062 ·Status: RECRUITING
-
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
NCT05081024 ·Status: RECRUITING
-
CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
NCT05027828 ·Status: RECRUITING
-
Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer
NCT05379907 ·Status: WITHDRAWN
-
Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer
NCT05285579 ·Status: UNKNOWN
-
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
NCT02948946 ·Status: COMPLETED
-
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
NCT05917106 ·Status: RECRUITING
-
Cell-free DNA Methylation Markers for Cancer Screening
NCT03096938 ·Status: UNKNOWN ·Phase: NA
-
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer
NCT03871816 ·Status: COMPLETED
-
Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer
NCT03214991 ·Status: UNKNOWN
-
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
NCT05685524 ·Status: UNKNOWN
-
Assessing Systemic Treatment and ctDNA Monitoring Efficacy in Metastatic Cancer Patients Using K4Care Testing.
NCT06929910 ·Status: RECRUITING
-
Circulating Tumor DNA Study in Patients With Endometrial Cancer
NCT05955079 ·Status: RECRUITING
-
Real-time Monitoring of Concentration and Size Variations of Circulating Plasma Free DNA to Predict Early Response to Immunotherapies in Patients With Different Types of Cancer.
NCT05083494 ·Status: UNKNOWN
-
Circulating Tumor DNA to Monitor the Efficacy of Total Neoadjuvant Therapy for Rectal Cancer
NCT05356585 ·Status: WITHDRAWN
-
Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients
NCT05343832 ·Status: UNKNOWN
-
Development of a Cell Free DNA Assay as a Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer
NCT03892096 ·Status: COMPLETED
-
Gastric Cancer Early Detection by Multi-dimensional Analysis of cfDNA
NCT05668910 ·Status: UNKNOWN
-
Circulating Free DNA Analysis in Gastrointestinal Cancer, Genitourinary Cancer, Rare Cancer
NCT02067754 ·Status: COMPLETED
-
Early Detection of Endometrial Cancer Using Plasma Cell-free DNA Fragmentomics
NCT06083779 ·Status: UNKNOWN
-
Registry Study in MSI/dMMR Solid Tumors
NCT06004713 ·Status: RECRUITING